Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate: Report of a case

作者：Ando Koji; Oki Eiji^*; Sugiyama Masahiko; Zhao Yan; Kojima Aya; Yamamoto Hidetaka; Yamashita Yoichi; Saeki Hiroshi; Taketomi Akinobu; Morita Masaru; Kakeji Yoshihiro; Tsujitani Shunichi; Maehara Yoshihiko

来源：Surgery Today, 2011, 41(9): 1290-1293.

DOI：10.1007/s00595-010-4477-8

• Extra-gastrointestinal stromal tumor
• KIT gene mutation
• Imatinib mesylate
• Secondary resistance

Extra-gastrointestinal stromal tumors (EGISTs) that do not originate in the digestive tract are rare. We report a case of multiple EGISTs, which was monitored closely by KIT gene mutation analysis and other investigations. The patient was a 52-year-old man in whom multiple tumors in the abdominal cavity were diagnosed as EGISTs. Immunohistochemical analysis revealed positive staining for c-kit; however, no mutations were found in the KIT gene. The tumors decreased in size remarkably following treatment with imatinib mesylate, but after 2 years of this treatment, multiple liver metastases and some regrowth of the abdominal masses were found simultaneously. The liver metastasis and the abdominal masses were excised, and further analysis of the KIT gene revealed the same mutation in exon 11 in the KIT gene in the metastatic tumors. We speculate that the treatment might have triggered development of the imatinib mesylate-resistant clone, which may have existed in the primary lesion as a KIT gene mutant. This report provides valuable insight into the mechanisms of recurrent GISTs after treatment with imatinib mesylate.

• 出版日期2011-9